These six stocks span numerous sectors, providing investors with opportunities in both growth and dividend yield.

By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, ...

Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

A new bill could make the price of prescription drugs known for weight loss cheaper for the state of Ohio to buy for its ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Ciara Lee reports.

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

A bill would allow Ohio state employees to purchase GLP-1s from manufacturers, then would require the Department of ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...